Rigel Pharmaceuticals (RIGL) Accumulated Expenses (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Accumulated Expenses of $6.0 million for Q1 2026, little changed year-over-year from $6.0 million in Q1 2025, and down 49.56% quarter-over-quarter from $11.9 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Accumulated Expenses (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $6.0 million for Q1 2026.
- In Q1 2026, Accumulated Expenses changed 0.25% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $6.0 million (changed 0.25% YoY), while the FY2025 annual figure was $11.9 million, up 17.51% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $6.0 million, down from $11.9 million in the prior quarter.
- The five-year high for Accumulated Expenses was $11.9 million in Q4 2025, with the low at $5.2 million in Q1 2024.
- The 5-year median for Accumulated Expenses is $7.9 million (2025), against an average of $7.8 million.
- The sharpest annual moves came in 2022 and 2025: Accumulated Expenses slipped 17.06% in 2022, then rose 27.02% in 2025.
- Rigel Pharmaceuticals' Accumulated Expenses stood at $8.9 million in 2022, then retreated by 2.14% to $8.7 million in 2023, then grew by 16.86% to $10.1 million in 2024, then climbed by 17.51% to $11.9 million in 2025, then sank by 49.56% to $6.0 million in 2026.
- Business Quant data shows RIGL's Accumulated Expenses at $6.0 million in Q1 2026, $11.9 million in Q4 2025, and $10.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.61 Mn |
| Mar 31, 2026 | 6.01 Mn |
| Dec 31, 2025 | 11.91 Mn |
| Sep 30, 2025 | 10.07 Mn |
| Jun 30, 2025 | 7.90 Mn |
| Mar 31, 2025 | 6.02 Mn |
| Dec 31, 2024 | 10.14 Mn |
| Sep 30, 2024 | 7.92 Mn |
| Jun 30, 2024 | 6.37 Mn |
| Mar 31, 2024 | 5.25 Mn |
| Dec 31, 2023 | 8.68 Mn |
| Sep 30, 2023 | 8.09 Mn |
| Jun 30, 2023 | 6.74 Mn |
| Mar 31, 2023 | 5.66 Mn |
| Dec 31, 2022 | 8.87 Mn |
| Sep 30, 2022 | 8.77 Mn |
| Jun 30, 2022 | 7.53 Mn |
| Mar 31, 2022 | 6.63 Mn |
| Dec 31, 2021 | 10.69 Mn |
| Sep 30, 2021 | 9.46 Mn |